PCSK9 antibodies (PCSK9i) have also shown effectiveness in reducing cardiovascular events in individuals with coronary artery disease who are intolerant to statin therapy.358 In a small study involving 11 PLWH with dyslipidemia not diagnosed with coronary artery disease and 19 PLWH with nearly optimal or above goal low-density lipoprotein cholesterol levels, the inhibition of PCSK9 with evolocumab demonstrated an improvement in abnormal coronary endothelial function.344 In this study, no improvement was reported in serum inflammation biomarkers. The gene discussed is PCSK9; the disease is coronary artery disorder.